Polymorphism of Renalase Gene in Patients of Chronic Kidney Disease


Introduction: Chronic kidney disease (CKD) is an important public health problem. Early detection and treatment is a key factor for prevention of its complications. Hypertensive nephrosclerosis is a subtype of CKD which has a poor correlation between hypertension and development of nephropathy, implying role of genetic factors or epigenetic factors. The knowledge regarding genetic factors is limited. Renalase is a novel hormone with its gene on chromosome 10, which secretes flavin adenine dinucleotide dependent amine oxidase. Renalase metabolizes circulating catecholamines and modulates blood pressure and cardiac function. Recently, two single nucleotide polymorphisms of renalase gene rs2576178 GG and rs2296545 CC have been linked to essential hypertension. The SNPrs2296545 CC is also shown to be associated with cardiac hypertrophy, dysfunction and ischemia. The association of these two single nucleotide polymorphisms with hypertensive nephrosclerosis has not been investigated. Methods: We designed a case-control study to investigate whether the two known renalase gene polymorphisms rs2576178 and rs2296545 are associated with CKD particularly hypertensive nephrosclerosis. We genotyped these two polymorphisms in 287 subjects from North Indian population (106 CKD cases and 181 controls). Results: Comparison shows that subjects with hypertensive nephrosclerosis had higher frequencies of rs2296545 Callele than the healthy controls (0.63 versus 0.47, p < 0.02). The odds ratio for rs2296545 CC genotype in hypertensive nephrosclerosis were 2.55 (95% CI, 1.03 to 6.42; p = 0.02) (CC versus GG) and 2.11(95% CI, 1.01 to 4.42; p = 0.03) (CC versus CG + GG) compared to controls. Conclusion: These findings may provide novel insight into the role of additional genomic regions as susceptibility gene in the pathophysiology of hypertensive nephrosclerosis. Further, to account for geoethnic variation, studies on heterogeneous populations involving a larger sample size are required. The correlation between this structural change and actual levels of the enzyme or the activity are required to strengthen this association as well as to be clinically applicable.

Share and Cite:

R. Ahlawat, S. Gupta, S. Kapoor and P. Kar, "Polymorphism of Renalase Gene in Patients of Chronic Kidney Disease," Open Journal of Nephrology, Vol. 2 No. 4, 2012, pp. 136-143. doi: 10.4236/ojneph.2012.24021.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] S. G. Satko, J. R. Sedor, S. K. Iyengar and B. I. Freedman, “Familial Clustering of Chronic Kidney Disease,” Seminars in Dialysis, Vol. 20, No. 4, 2007, pp. 229-236. doi:10.1111/j.1525-139X.2007.00282.x
[2] C. S. Fox, Q. Yang, L. A. Cupples, C. Y. Guo, M. G. Larson, E. P. Leip, et al., “Genome Wide Linkage Analysis to Serum Creatinine, GFR, and Creatinine Clearance in a Community-Based Population: The Framingham Heart Study,” Journal of the American Society of Nephrology, Vol. 15, No. 9, 2004, pp. 2457-2461. doi:10.1097/01.ASN.0000135972.13396.6F
[3] P. P. Faronato, M. Maioli, G. Tonolo, E. Brocco, F. Noventa, F. Piarulli, et al., “Clustering of Albumin Excretion Rate Abnormalities in Caucasian Patients with NIDDM. The Italian NIDDM Nephropathy Study Group,” Diabetologia, Vol. 40, No. 7, 1997, pp. 816-823. doi:10.1007/s001250050754
[4] W. M. McClellan, S. G. Satko, E. Gladstone, J. O. Krisher, A. S. Narva and B. I. Freedman, “Individuals with a Family History of ESRD Are a High-Risk Population for CKD: Implications for Targeted Surveillance and Intervention Activities,” American Journal of Kidney Diseases, Vol. 53, Suppl. 3, 2009, pp. S100-S106.
[5] J. Coresh, E. Selvin, L. A. Stevens, J. Manzi, J. W. Kusek, P. Eggers, et al., “Prevalence of Chronic Kidney Disease in the United States,” Journal of the American Medical Association, Vol. 298, No. 17, 2007, pp. 2038-2047. doi:10.1001/jama.298.17.2038
[6] Q. L. Zhang and D. Rothenbacher, “Prevalence of Chronic Kidney Disease in Population-Based Studies: Systematic Review,” BMC Public Health, Vol. 8, 2008, pp. 117. doi:10.1186/1471-2458-8-117
[7] M. K. Haroun, B. G. Jaar, S. C. Hoffman, G. W. Comstock, M. J. Klag and J. Coresh, “Risk Factors for Chronic Kidney Disease: A Prospective Study of 23,534 Men and Women in Washington Country, Maryland,” Journal of the American Society of Nephrology, Vol. 14, No. 11, 2003, pp. 2934-2941. doi:10.1097/01.ASN.0000095249.99803.85
[8] F. C. Luft, “Hypertensive Nephrosclerosis: Update,” Current Opinion in Nephrology and Hypertension, Vol. 13, No. 2, 2004, pp. 147-154. doi:10.1097/00041552-200403000-00002
[9] B. I. Freedman, S. S. Iskandar and R. G. Appel, “The Link between Hypertension and Nephrosclerosis,” American Journal of Kidney Diseases, Vol. 25, No. 2, 1995, pp. 207-221. doi:10.1016/0272-6386(95)90001-2
[10] C. Y. Hsu, “Does Non-malignant Hypertension Cause Renal Insufficiency? Evidence-Based Perspective,” Current Opinion in Nephrology and Hypertension, Vol. 11, No. 3, 2002, pp. 267-272. doi:10.1097/00041552-200205000-00001
[11] J. A. Sarnak, T. Greene, X. Wang, G. Beck, J. W. Kusek, A. J. Collins, et al., “The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-Up of the Modification of Diet in Renal Disease Study,” Annals of Internal Medicine, Vol. 142, No. 5, 2005, pp. 342-351.
[12] A. Siewert-Delle, S. Ljungman, O. K. Andersson and L. Wilhelmsen, “Does Treated Primary Hypertension Lead to End-Stage Renal Disease? A 20-Year Follow-Up of the Primary Prevention Study in G?teborg, Sweden,” Nephrology Dialysis Transplantation, Vol. 13, No. 12, 1998, pp. 3084-3090. doi:10.1093/ndt/13.12.3084
[13] C. Y. Hsu, C. E. McCulloch, J. Darbinian, A. S. Go and C. Iribarren, “Elevated Blood Pressure and Risk of End-Stage Renal Disease in Subjects without Baseline Kidney Disease,” Archives of Internal Medicine, Vol. 165, No. 8, 2005, pp. 923-928. doi:10.1001/archinte.165.8.923
[14] L. Zarif, A. Covic, S. Iyengar, A. R. Sehgal, J. R. Sedor and J. R. Schelling, “Inaccuracy of Clinical Phenotyping Parameters for Hypertensive Nephrosclerosis,” Nephrology Dialysis Transplantation, Vol. 15, No. 11, 2000, pp. 1801-1807. doi:10.1093/ndt/15.11.1801
[15] R. B. Toto, “Hypertensive Nephrosclerosis in African Americans,” Kidney International, Vol. 64, No. 6, 2003, pp. 2331-2341. doi:10.1046/j.1523-1755.2003.00333.x
[16] R. Marín, M. Gorostidi, F. Fernández-Vega and R. álvarez-Navascués, “Systemic and Glomerular Hypertension and Progression of Chronic Renal Disease: The Dilemma of Nephrosclerosis,” Kidney International Supplements, Vol. 99, Suppl. 99, 2005, pp. S52-S56. doi:10.1111/j.1523-1755.2005.09910.x
[17] W. M. McClellan, S. G. Satko, E. Gladstone, J. O. Krisher, A. S. Narva and B. I. Freedman, “Individual with a Family History of ESRD Are a High Risk Population for CKD: Implications for Targeted Surveillance and Intervention Activities,” American Journal of Kidney Diseases, Vol. 53, Suppl. 3, 2009, pp. S100-S106. doi:10.1053/j.ajkd.2008.07.059
[18] W. H. Kao, M. J. Klag, L. A. Meoni, D. Reich, Y. Berthier-Schaad, M. Li, et al.,“MYH9 is Associated with Nondiabetic End Stage Renal Disease in African Americans,” Nature Genetics, Vol. 40, No. 10, 2008, pp. 1185-1192. doi:10.1038/ng.232
[19] K. Anbazhagan, K. Sampathkumar, M. Ramakrishnan, S. Gomathi and G. S. Selvam, “Analysis of Polymorphism in Renin Angiotensin System and Other Related Genes in South Indian Chronic Kidney Disease Patients,” Clinica Chimica Acta, Vol. 406, No. 1-2, 2009, pp. 108-112. doi:10.1016/j.cca.2009.06.003
[20] J. Xu , G. Li, P. Wang, H. Velazquez, X. Yao, Y. Li, et al., “Renalase Is a Novel, Soluble Monoamine Oxidase that Regulates Cardiac Function and Blood Pressure,” Journal of Clinical Investigation, Vol. 115, No. 5, 2005, pp. 1275-1280.
[21] G. V. Desir, “Regulation of Blood Pressure and Cardiovascular Function by Renalase,” Kidney International, Vol. 76, No. 2009, pp. 366-370. doi:10.1038/ki.2009.169
[22] G. Desir, P. Wang and H. Velazquez, “On the Mechanisms Mediating the Cardioprotective Effect of Renalase,” Journal of the American Society of Nephrology, 2009. http://www.asn-online.org/education_and_meetings/renal_week/archives/
[23] S. S. Ghosh, T. W. B. Gehr and D. A. Sica, “Renalase Regulates Blood Pressure in Salt Sensitive Dahl Rats,” Journal of the American Society of Nephrology, Vol. 17, 2006, p. 208A.
[24] G. Desir, L. Tang, P. Wang, G. Li and H. Velazquez, “Antihypertensive Effect of Recombinant Renalase in Dahl Salt Sensitive (DSS) Rats,” 2010. http://www.asn-online.org/education_and_meetings/renal_week/archives/
[25] G. V. Desir, “Renalase Deficiency in Chronic Kidney Disease, and Its Contribution to Hypertension and Cardiovascular Disease,” Current Opinion in Nephrology and Hypertension, Vol. 17, No. 2, 2008, pp. 181-185. doi:10.1097/MNH.0b013e3282f521ba
[26] M. Schlaich, F. Socratous and N. Eikelis, “Renalase Plasma Levels Are Associated with Systolic Blood Pressure in Patients with Resistant Hypertension,” Journal of Hypertension, Vol. 28, 2010, pp. e434-e435. doi:10.1097/01.hjh.0000379519.82971.02
[27] Y. Wu, J. Xu, H. Velazquez, P. Wang, G. Li, D. Liu, et al., “Renalase Deficiency Aggravates Ischemic Myocardial Damage,” Kidney International, Vol. 79, No. 8, 2011, pp. 853-860. doi:10.1038/ki.2010.488
[28] Q. Zhao, Z. Fan, J. He, S. Chen, H. Li, P. Zhang, et al., “Renalase Gene Is a Novel Susceptibility Gene for Essential Hypertension: A Two-Stage Association Study in Northern Han Chinese Population,” Journal of Molecular Medicine, Vol. 85, No. 8, 2007, pp. 877-885. doi:10.1007/s00109-006-0151-4
[29] R. Farzaneh-Far, G. V. Desir, N. B. Schiller and M. A. Whooley, “A Functional Polymorphism in Renalase (Glu37Asp) Is Associated with Cardiac Hypertrophy, Dys- function, and Ischemia: Data from the Heart and Soul Study,” PLoS One, Vol. 5, No. 10, 2010, pp. e13496. doi:10.1371/journal.pone.0013496
[30] D. Ojea, R. Marin, E. Coto, et al., “Clinical and Genetic Basis of Hypertensive Nephrosclerosis,” Nefrologia, Vol. 30, No. 6, 2010, pp. 687-697.
[31] A. S. Levey, J. Coresh, E. Balk, A. T. Kausz, A. Levin, M. W. Steffes, et al., “National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification,” Annals of Internal Medicine, Vol. 139, No. 2, 2003, pp. 137-147.
[32] A. Fogo, J. A. Breyer, M. C. Smith, W. H. Cleveland, L. Agodoa, K. A. Kirk, et al., “Accuracy of the Diagnosis of Hypertensive Nephrosclerosis in African Americans: A Report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators,” Kidney International, Vol. 51, No. 1, 1997, pp. 244-252.
[33] B. I. Freedman, P. J. Hicks, M. A. Bostrom, M. E. Cunningham, Y. Liu, J. Divers, et al., “Polymorphisms in the Non-muscle Myosin Heavy Chain 9 Gene (MYH9) Are Strongly Associated with End-stage Renal Disease Historically Attributed to Hypertension in African Americans,” Kidney International, Vol. 75, No. 7, 2009, pp. 736-745. doi:10.1038/ki.2008.701

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.